BioVie (BIVI) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
8 Jul, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with board members and key executives in attendance virtually.
Independent public accountants and outside securities counsel also present.
Secretary appointed to record minutes and confirm formal meeting procedures.
Corporate governance
Record date for voting set as September 30, 2024, with 7,956,660 shares outstanding.
Notice of meeting and proxy materials mailed to shareholders on October 9, 2024.
Quorum established with over 60% of shares represented.
Overview of voting outcomes
Six directors elected for a one-year term by plurality of votes.
Auditor ratification approved with 93.2% of represented shares.
Say-On-Pay Proposal approved with 93.9% support.
Amendment to the 2019 Omnibus Equity Incentive Plan approved with 92.6% support.
Latest events from BioVie
- Best efforts IPO seeks $22.7M for neuro and liver drug R&D, with up to 16M shares and warrants.BIVI
Registration filing - Net loss rose to $22.1M in FY2026; ongoing clinical trials and funding needs raise going concern doubts.BIVI
Q4 2026 - Bezisterim improved motor, non-motor symptoms, and biomarkers, supporting Phase III advancement.BIVI
Study result - Biotech seeks $70M in best efforts IPO to fund R&D amid ongoing losses and litigation risks.BIVI
Registration filing - Biotech seeks up to $70M via share and warrant offering to fund R&D, facing high risk and dilution.BIVI
Registration filing - Biotech seeks capital for late-stage neuro and liver drug programs amid ongoing losses and legal risks.BIVI
Registration filing - Bezisterim targets neuroinflammation in early Parkinson's with a novel, patient-friendly trial design.BIVI
Status Update - Biotech seeks to raise up to $300M for neuro and liver disease R&D via flexible securities offering.BIVI
Registration filing - Imminent clinical data for Parkinson's and Long COVID could unlock major market opportunities.BIVI
Investor update